Research programme: monoclonal antibody therapeutics - AVEO

Drug Profile

Research programme: monoclonal antibody therapeutics - AVEO

Alternative Names: AV-232; AV-323; AV-325; AV-353; AV-368; AV-369; AV-370; AV-371; AV-378; AV-380

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator St Vincents Hospital, Sydney
  • Developer AVEO Oncology
  • Class Monoclonal antibodies
  • Mechanism of Action Growth differentiation factor 15 inhibitors; Hepatocyte growth factor inhibitors; Immunomodulators; Notch signalling pathway inhibitors; Notch-3 receptor antagonists; Proto oncogene protein c met inhibitors; RON protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - Cachexia; Pulmonary arterial hypertension

Highest Development Phases

  • Preclinical Pulmonary arterial hypertension
  • No development reported Cachexia; Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cachexia in USA (Parenteral)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
  • 08 May 2017 AVEO Oncology receives Notice of allowance for a patent related to AV 353 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top